ZZ-FIRST II 期试验:talazoparib 联合 enzalutamide 治疗高体积转移性激素敏感前列腺癌
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
ZZ-FIRST 随机多中心 II 期试验显示,在高体积转移性激素敏感前列腺癌患者中,PARP 抑制剂 talazoparib 联合 AR 抑制剂 enzalutamide 治疗组的前列腺特异性抗原应答优于单药 enzalutamide。配对活检的空间转录组分析表明,AR 抑制诱导的 HRR 相关程序抑制与增殖停滞相关,而非功能性 HRR 缺陷。
ZZ-FIRST II 期结果提供前列腺特异性抗原应答数据,并解释 PARPi 与 AR 抑制剂联用的机制关联。
Nature Medicine, Published online: 14 October 2026; doi:10.1038/s41591-026-04671-5
In the randomized multicenter phase 2 ZZ-FIRST trial, patients with high-volume metastatic hormone-sensitive prostate cancer treated with poly(ADP-ribose) polymerase inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved prostate-specific antigen response compared with enzalutamide alone, and spatial transcriptomic analyses of paired biopsies linked AR inhibition-induced suppression of HRR-related programs to proliferation arrest rather than functional HRR deficiency.
来源:Nature Medicine · nature.com